SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF A FOREIGN ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For May 22, 2020

Commission File Number 1-38455

 

 

MorphoSys AG

 

 

Semmelweisstrasse 7

82152 Planegg

Germany

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

If ‘‘Yes’’ is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):             

 

 

 

Exhibits

 

99.1    MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    MORPHOSYS AG (Registrant)
Date: May 22, 2020     By:  

/s/ Jens Holstein

    Name:   Jens Holstein
    Title:   CFO
    By:  

/s/ Charlotte Lohmann

    Name:   Charlotte Lohmann
    Title:   General Counsel
MorphoSys (PK) (USOTC:MPSYF)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more MorphoSys (PK) Charts.
MorphoSys (PK) (USOTC:MPSYF)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more MorphoSys (PK) Charts.